|Combination antiretroviral therapy and the risk of myocardial infarction|
Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
New England Journal of Medicine 349 (21), 1993-2003, 2003
|HLA-B* 5701 screening for hypersensitivity to abacavir|
S Mallal, E Phillips, G Carosi, JM Molina, C Workman, J Tomažič, ...
New England Journal of Medicine 358 (6), 568-579, 2008
|Association between presence of HLA-B* 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir|
S Mallal, D Nolan, C Witt, G Masel, AM Martin, C Moore, D Sayer, ...
The Lancet 359 (9308), 727-732, 2002
|A whole-genome association study of major determinants for host control of HIV-1|
J Fellay, KV Shianna, D Ge, S Colombo, B Ledergerber, M Weale, ...
science 317 (5840), 944-947, 2007
|Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration|
D: A: D Study Group
The Lancet 371 (9622), 1417-1426, 2008
|Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level|
CB Moore, M John, IR James, FT Christiansen, CS Witt, SA Mallal
Science 296 (5572), 1439-1443, 2002
|Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA|
P Kiepiela, AJ Leslie, I Honeyborne, D Ramduth, C Thobakgale, S Chetty, ...
Nature 432 (7018), 769-775, 2004
|Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection|
SA Mallal, M John, CB Moore, IR James, EJ McKinnon
Aids 14 (10), 1309-1316, 2000
|The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases|
P Price, C Witt, R Allock, D Sayer, M Garlepp, CC Kok, M French, S Mallal, ...
Immunological reviews 167 (1), 257-274, 1999
|Immune restoration disease after the treatment of immunodeficient HIV‐infected patients with highly active antiretroviral therapy|
MA French, N Lenzo, M John, SA Mallal, EJ McKinnon, IR James, P Price, ...
HIV medicine 1 (2), 107-115, 2000
|Predisposition to abacavir hypersensitivity conferred by HLA-B* 5701 and a haplotypic Hsp70-Hom variant|
AM Martin, D Nolan, S Gaudieri, CA Almeida, R Nolan, I James, ...
Proceedings of the National Academy of Sciences 101 (12), 4180-4185, 2004
|Adaptation of HIV-1 to human leukocyte antigen class I|
Y Kawashima, K Pfafferott, J Frater, P Matthews, R Payne, M Addo, ...
Nature 458 (7238), 641-645, 2009
|Common genetic variation and the control of HIV-1 in humans|
J Fellay, D Ge, KV Shianna, S Colombo, B Ledergerber, ET Cirulli, ...
PLoS genetics 5 (12), 2009
|Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes|
B Ledergerber, PLATO collaboration
The Lancet 364 (9428), 51-62, 2004
|Effects of CCR5-32, CCR2-64I, and SDF-1 3 A Alleles on HIV-1 Disease Progression: An International Meta-Analysis of Individual-Patient Data|
Ann Intern Med 135, 782-795, 2001
|Predisposition to nevirapine hypersensitivity associated with HLA-DRB1* 0101 and abrogated by low CD4 T-cell counts|
AM Martin, D Nolan, I James, P Cameron, J Keller, C Moore, E Phillips, ...
Aids 19 (1), 97-99, 2005
|Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 …|
TM Allen, M Altfeld, SC Geer, ET Kalife, C Moore, KM O'Sullivan, ...
Journal of virology 79 (21), 13239-13249, 2005
|High sensitivity of human leukocyte antigen-b* 5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients|
M Saag, R Balu, E Phillips, P Brachman, C Martorell, W Burman, B Stancil, ...
Clinical infectious diseases 46 (7), 1111-1118, 2008
|Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy|
M John, CB Moore, IR James, D Nolan, RP Upton, EJ McKinnon, ...
Aids 15 (6), 717-723, 2001
|Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study|
A Rauch, D Nolan, A Martin, E McKinnon, C Almeida, S Mallal
Clinical infectious diseases 43 (1), 99-102, 2006